Samjin Pharmaceutical and AriBio are accelerating clinical trial preparations to develop a homegrown dementia treatment.Samjin and AriBio said Wednesday that they completed an expert meeting, "POLARIS AD AR1001 Global PⅢ Trial Meeting," last Friday and Saturday ahead of the domestic phase 3 clinical
CanariaBio, a Korean biotech company listed on Kosdaq, said it has entered into an exclusive distribution and license agreement with Hikma MENA FZE for the commercialization of oregovomab, an immunotherapy for ovarian cancer, in the Middle East and North Africa (MENA) region.Hikma MENA FTZ, which wi
A series of recent drug mispackaging incidents have put the manufacturing process management of domestic pharmaceutical companies under scrutiny.This time, the mix-up incident involved a dyslipidemia drug produced by Daewon Pharmaceutical. The incident's aftermath will be closely watched as Daewon p
Baxter Korea on Tuesday announced the release of Olimel N12E, a protein-rich Total Parenteral Nutrition (TPN) fluid for critically ill patients, with health insurance coverage beginning on Oct. 1.Olimel N12E contains 76 grams of amino acids and 950 calories per 1,000 mL, marking an approximately 33
SK plasma said that it has signed a term sheet with the Indonesia Investment Authority (INA) for the establishment of its blood products plant in Indonesia.The company's spokesperson did not reveal the exact location of the plant but said it would be near Jakarta. INA was established in Nov. 2020 an
Hanmi Pharm said Tuesday it participated in a symposium organized by Congenital Hyperinsulinism International (CHI) in The Hague, Netherlands, from Sept. 22-24 to introduce its LAPS GLP-2 analog, HM15912, under development to treat the disease.CHI is a non-profit organization founded in 2005 to impr
As the opening of the European Society for Medical Oncology Annual Meeting (ESMO 2023), Europe's largest cancer conference, draws near, attention here is focused on Korean participants.Along with the American Society of Clinical Oncology (ASCO) and the American Association of Cancer Research (AACR),
Eight out of 10 patients administered the ultra-expensive drug, Kymriah Inj., which costs hundreds of millions of won, did not achieve meaningful therapeutic results, a lawmaker pointed out.The legislator emphasized the need to increase the reimbursement rate for pharmaceutical companies if these ex
GC Cell said on Friday that it signed an agreement with IQVIA, the world's largest contract research organization (CRO), to conduct a multicountry phase 1 clinical trial of its CAR-NK cell therapy targeting solid tumors, AB201.Accordingly, GC Cell plans to conduct multicountry clinical trials of AB-
Seoul National University Bundang Hospital (SNUBH) announced that its researchers have secured 1.6 billion won ($1.18 million) in research funding for conducting clinical research using artificial intelligence (AI) to select the best embryos for implantation during in vitro fertilization (IVF).Profe
Despite Korea reducing Covid-19 emergency response levels, immunology experts elaborated that the only way to keep the virus under control was through seasonal updated vaccination to adapt to the mutating virus. In response, Moderna Korea held a press conference on Thursday to share data on the clin
GC Biopharma said on Thursday that its drug candidate to treat thrombotic thrombocytopenic purpura (GC1126A) has received orphan drug designation from the U.S. FDA on Sept. 27.Accordingly, the orphan drug designation will provide tax breaks on research and development expenses, exemption from permit
Lotte Biologics said on Wednesday that it signed a land purchase agreement with the Incheon Free Economic Zone Authority (IFEZ) to build three bioprocessing plants in Songdo, Incheon, by 2030.The plants will be situated at Songdo International Business District, Block KI20 in Zone 11, and will have
GSK Korea said on Wednesday that it appointed Maurizio Borgatta as its new general manager as of Oct. 1.Borgatta will fill the shoes of outgoing GSK Korea General Manager, Rob Kempton, who has led GSK Korea since 2020. Subsequently, Kempton will serve as Head of the Vaccines Market in Europe.Since j
Handok said on Wednesday that it entered into a strategic partnership with global biopharmaceutical company Sobi to strengthen its rare disease business. Sobi, a Swedish biopharmaceutical specializing in rare diseases, provides innovative therapies in hematology, immunology, and specialty care, with
Korean pharmaceutical companies are stepping up competition to develop microneedle patch-type obesity treatments, often called “adhesive obesity drugs.”Four companies -- Daewon Pharmaceutical, Dong-A ST, Kwangdong Pharmaceutical, and Daewoong Group – have joined the competition.According to industry
Celltrion said on Wednesday that it received approval from the FDA for its 80 mg and 20 mg dosage forms of Yuflyma, a biosimilar referencing Abbvie's Humira (ingredient: adalimumab), adding to the existing approval for the 40 mg dose. Humira, the original medicine, is prescribed primarily for autoim
Roche Korea said on Wednesday that its oral treatment for spinal muscular atrophy (SMA), Evrysdi (ingredient: risdiplam), obtained health insurance coverage from Oct.1.Accordingly, Evrysdi will be covered for patients with 5q SMA with a confirmed genetic diagnosis of a deletion or mutation in the 5q
Handok said on Wednesday that it submitted an IND plan for a global phase 2/3 clinical trial of HDB001A, a biliary tract cancer drug candidate, to the Ministry of Food and Drug Safety (MFDS). The global phase 2/3 study of HDB001A will enroll 150 patients at more than 35 sites in Korea and overseas.
Bridge Biotherapeutics announced on Tuesday that it will discontinue the development of BBT-176, a drug candidate for non-small cell lung cancer (NSCLC), and BBT-212, another candidate for fundus disease.Instead, the company stated it would focus on BBT-877 and BBT-207, candidates for idiopathic pul